- Home
- CMP vs ERAS Comparison
CMP vs ERAS Comparison
Compare CMP & ERAS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CMP
- ERAS
- Stock Information
- Founded
- CMP 1993
- ERAS 2018
- Country
- CMP United States
- ERAS United States
- Employees
- CMP N/A
- ERAS N/A
- Industry
- CMP Other Metals and Minerals
- ERAS Biotechnology: Pharmaceutical Preparations
- Sector
- CMP Basic Materials
- ERAS Health Care
- Exchange
- CMP Nasdaq
- ERAS Nasdaq
- Market Cap
- CMP 493.5M
- ERAS 432.6M
- IPO Year
- CMP 2003
- ERAS 2021
- Fundamental
- Price
- CMP $11.09
- ERAS $1.17
- Analyst Decision
- CMP Buy
- ERAS Strong Buy
- Analyst Count
- CMP 3
- ERAS 6
- Target Price
- CMP $18.33
- ERAS $4.83
- AVG Volume (30 Days)
- CMP 686.3K
- ERAS 2.3M
- Earning Date
- CMP 05-06-2025
- ERAS 05-07-2025
- Dividend Yield
- CMP N/A
- ERAS N/A
- EPS Growth
- CMP N/A
- ERAS N/A
- EPS
- CMP N/A
- ERAS N/A
- Revenue
- CMP $1,082,900,000.00
- ERAS N/A
- Revenue This Year
- CMP $4.89
- ERAS N/A
- Revenue Next Year
- CMP $7.00
- ERAS N/A
- P/E Ratio
- CMP N/A
- ERAS N/A
- Revenue Growth
- CMP N/A
- ERAS N/A
- 52 Week Low
- CMP $7.51
- ERAS $1.01
- 52 Week High
- CMP $15.82
- ERAS $3.45
- Technical
- Relative Strength Index (RSI)
- CMP 61.55
- ERAS 41.92
- Support Level
- CMP $8.60
- ERAS $1.01
- Resistance Level
- CMP $11.24
- ERAS $1.29
- Average True Range (ATR)
- CMP 0.56
- ERAS 0.17
- MACD
- CMP 0.25
- ERAS 0.00
- Stochastic Oscillator
- CMP 91.48
- ERAS 29.63
About CMP Compass Minerals Intl Inc
Compass Minerals currently produces two primary products: salt and specialty potash fertilizer. The company's main assets include rock salt mines in Ontario, Louisiana, and the United Kingdom. The fertilizer is produced from a brine operation at the Great Salt Lake in Utah that produces sulfate of potash and magnesium chloride. Compass' salt products are used for deicing and also by industrial and consumer end markets. The firm's sulfate of potash is used by growers of high-value crops that are sensitive to standard potash.
About ERAS Erasca Inc.
Erasca Inc is a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers. The company's pipeline includes; Naporafenib, a pan-RAF inhibitor with first-in-class potential in NRASm melanoma, RAS Q61X tissue agnostic solid tumors, and other RAS/MAPK pathway-driven tumors, and ERAS-007 (oral ERK1/2 inhibitor) and ERAS-601 (oral SHP2 inhibitor), which target downstream and upstream nodes, respectively, of the RAS/MAPK pathway.